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oligonucleotide arrays. Applying both an unsupervised hierarchical
clustering analysis and a supervised Bayesian ANOVA analysis, 300
genes from these analyses were classiﬁed as being either membrane
bound or soluble gene products based on the database of mem-
brane-associated/soluble gene products generated by Diehn et al.
(PLoS Genetics epub 2006). Thirty-two of these were annotated to
be secreted gene products. Several novel growth factors not typi-
cally associated with hematopoiesis were identiﬁed. We have found
that one of these factors, adrenomedullin, a vasodilator not known
to have hematopoietic function, induces the proliferation of human
BM CD34CD38-lin- HSCs in single cell cultures and promotes
the quantitative expansion of human BM CD34 progenitor cells
in vitro. This molecular signature of HUBECs provides a unique
resource for the discovery and characterization of novel soluble
factors that regulate human HSC fate.
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HSC, sorted as KSL (c-KitSca-1Lin-) cells, are comprised of
primitive long-term repopulating cells and short-term repopulat-
ing committed progenitors. Growth factors such as GM-CSF,
G-CSF or Flt3-ligand (FL) are utilized to expand and mobilize
HSC. We evaluated here the phenotype and function of FL-
mobilized HSC. FL signiﬁcantly expands c-Kithi and c-Kitlo KSL
cells in peripheral blood (PB). Only FL-expanded PB c-Kithi KSL
cells exhibited high spleen colony-forming unit frequency, gener-
ated high numbers of both lymphoid and myeloid colonies in vitro,
and rescued ablated recipients. FL expanded two subsets of c-Kithi
KSL cells: CD34ﬂt3- reﬂective of short-term HSC (ST-HSC)
and CD34-ﬂt3- long-term HSC (LT-HSC), while the proportion
of c-Kithi CD34ﬂt3 KSL cells multipotent progenitors (MPP)
was signiﬁcantly decreased in the PB. When 500 CD34ﬂt3-,
CD34ﬂt3 or CD34-ﬂt3- c-Kithi KSL cells were transplanted
into ablated syngeneic recipients, all recipients of CD34ﬂt3
c-Kithi KSL expired within 16 days (n 5). One of the 5 recipients
of c-Kithi CD34ﬂt3- KSL (ST-HSC) survived over 120 days. The
combination of 50 c-Kithi CD34-ﬂt3- KSL cells (LT-HSC) with
500 c-Kithi CD34ﬂt3- or CD34ﬂt3 KSL cells enhanced recip-
ient survival (4/6 recipients of both ST-HSC plus LT-HSC sur-
vived over 120 days and some recipients of MPP  LT-HSC
survived up to 68 days ). These data suggest that ﬂt3 expression
may be a useful phenotypic marker for selecting critical stem cell
populations to ensure rapid and durable engraftment and conﬁrms
that both short and long-term repopulating cells are needed for
optimal successful transplantation.
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ABILITY OF ANTI C-KIT TARGETING MONOCLONAL ANTIBODY ACK-2
TO TARGET HEMATOPOIETIC STEM CELLS, AND FACILITATE ENGRAFT-
MENT OF HUMAN CD34 ENGRAFTMENT AND HEMATOLYMPHOID
DEVELOPMENT IN IMMUNODEFICIENT MICE: A NOVEL ANTIBODY
BASED CONDITIONING STRATEGY
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INTRODUCTION: The stem cell receptor factor receptor,
c-Kit, is expressed on hematopoeitic stem (HSC) and progenitor
cell populations and may serve as a target molecule for manipula-
tion of host HSC & their niche. ACK2 is an anti-mouse c-Kit mAb
which has been shown to antagonize the function of c-kit and
deplete the bone marrow. We wished to characterize the effect &
kinetics of ACK2 on blood cell counts and marrow hematopoetic
stem cell (HSC) and progenitor populations. We also sought to
test the hypothesis that treatment with an HSC targeting mAb may
serve as an novel antibody based conditioning strategy as well as a
means for enhancing human HSC engraftment in immunodeﬁ-
cient mice by selectively inhibiting murine HSC.
METHODS: Adult C57/BL mice were injected with anti
1-500ug of ACK2 mAb & peripheral blood counts, as well as
marrow HSC and progenitor frequency were followed. Subse-
quently, we examined the ability of ACK2 to enhance human
engraftment in sublethally irradiated (4Gy) immunodeﬁcient
RAG2/Common Gamma-Chain double knock out (RAG2-DKO)
pups injected intrahepatically with 1-510^5 CD34 cells from
human mobilized peripheral blood (hCD34).
RESULTS: Administration of ACK2 resulted in rapid develop-
ment of anemia, neutropenia & thrombocytopenia. In treated
mice, the mean number & bone marrow fraction of Long-Term
HSC decreased markedly from .07% of total marrow cells in
controls to .003% in ACK2 treated mice as did the marrow num-
ber/frequency of CMP, GMP, and CMP. Human CD34 trans-
planted RAG-2 DKO mice treated with ACK2 engrafted at a
higher rate (46% vs 27% of controls achieved 10% human
chimerism) with higher human CD45 chimerism in blood, bone
marrow, spleen, liver, & lymph nodes. Robust human thymopoeisis
was observed with a mean of 63% of cells within the thymus
human derived. We found differentiation of mature human T-cells
occured via a CD3-48- intermediate a pathway identical to that
which we found in human stroma in SCID-hu T-cell development.
The ability for host ACK2 conditioning alone to enable donor
murine HSC engraftment will be presented.
CONCLUSIONS: Anti c-kit mAb treatment rapidly induces
pancytopenia with correlating decreases in the numbers of marrow
HSC and other progenitor populations and may serve as a strategy
for host HSC targeted mAb based conditioning. ACK-2 enhances
the frequency and degree of human CD34 engraftment and
human thymopoiesis and may serve as a means to enhance this new
model of human hematopoiesis.
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The capacity of recombinant Hoxb4 protein to induce ex vivo
expansion of hematopoietic stem cells (HSCs) identiﬁes this pro-
tein as a potential HSC expanding factor. However, its short extra-
and intra-cellular half-life (3-4 hours and 40-60 minutes, respec-
tively) hampers clinical applications of Hoxb4. The analyses of
Hoxb4 molecular structure lead us to generate amino acid substi-
tutions: (A) Leu73Ala, (B) Tyr233Ala and (C) Tyr283Ala in
the Hoxb4 protein in order to promote its stability. Indeed, these
modiﬁcations increased the intracellular stability of Hoxb4 protein
3-fold compared to wild type Hoxb4 (Hoxb4(WT)). The ability
of mutated Hoxb4 protein to favor expansion of hematopoietic
progenitors was ﬁrst examined in cultures initiated with 10%
Hoxb4(WT)-GFP, 10% mutated Hoxb4-YFP expressing cells and
80% non-transduced cells. After an 18-day culture, the proportion
of A and B Hoxb4 mutants cells increased to 50-60% in compar-
ison to 30% for Hoxb4(WT) (p 0.05), and no difference between
the proliferation of C Hoxb4 mutant and Hoxb4(WT) cells could
be identiﬁed. Western blot analyses showed that the A and B
Hoxb4 mutants expressed  4-fold higher and C Hoxb4 mutant
cells  8-fold lower levels of Hoxb4 protein than Hoxb4(WT)
cells. The long-term reconstituting ability of these constructs was
then evaluated in vivo using competitive repopulation assays. At 8
and 16 weeks after transplantation, A and B Hoxb4 mutants con-
tributed less peripheral blood and BM leukocytes (PBL) than
Hoxb4(WT). Flow cytometry analysis of bone marrow, spleen and
thymus revealed that mutated Hoxb4, like Hoxb4(WT) was ex-
pressed by all hematopoietic lineages, and that repopulation dif-
ferences observed between mutated and WT Hoxb4 expressing
cells were almost entirely attributable to myeloid lineage cells.
However, non-competitive repopulation experiments showed that
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